On June 24th, Hutchmed (China) announced that its partner, Takeda (TSE: 4502 / NYSE: TAK), received approval from the European Commission for FRUZAQLA (futulintib), as a monotherapy for the treatment of adult patients with metastatic colorectal cancer who have previously received fluoropyrimidine-base chemotherapy, oxaliplatin and irinotecan-based chemotherapy, anti-vascular endothelial growth factor (VEGF) therapy, and antiepidermal growth factor receptor (EGFR) therapy, as well as in patients with disease progression or intolerance after treatment with trifluorothymidine-tipiracil or regorafenib.Dr. Josep Tabernero, Director of the Vall d'Hebron Institute of Oncology (VHIO) in Barcelona, Spain, said: 'Fruquintinib is the first and only selective inhibitor of all three VEGFR subtypes approved in the EU for the treatment of colorectal cancer. This decision marks an important milestone in European oncology. In Europe, patients with treated metastatic colorectal cancer and their clinicians urgently need new treatment options. We are pleased to take an important step forward and prescribe this new and differentiated drug for patients.'
Teresa Bitetti, President of Takeda's global oncology division, said: 'We are pleased that FRUZAQLA has been approved by the European Commission, and we can now provide new treatment options for treated metastatic colorectal cancer patients, regardless of their biomarker status. For a long time, patients with treated metastatic colorectal cancer in Europe have been waiting for new treatment options, and we are honored to be able to meet this need through our collaboration with Hutchmed (China).'
Dr. Su Weliguo, CEO and CSO of Hutchmed (China), said: 'This is an important milestone for Hutchmed (China). This is the first product approved by our R&D engine in Europe, and we have achieved this goal in such a short period of time through our collaboration with Takeda. Currently, this innovative anti-cancer drug is improving the prospects of treating this disease in the United States and China, and we also look forward to bringing its impact to patients in Europe.'Please refer to Translatable 0-3 for complete translation.
Please refer to Translatable 3 for complete translation.